Drug intelligence / Profile preview

rilvegostomig + ramucirumab

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**Rilvegostomig + ramucirumab** is an investigational combination of two monoclonal antibodies aimed at treating advanced or metastatic non-small cell lung cancer (NSCLC). **Rilvegostomig** (code name AZD2936) is a novel therapeutic antibody, while **ramucirumab** (brand name Cyramza) is a recombinant human IgG1 monoclonal antibody targeting VEGFR-2 to inhibit angiogenesis. The combination is designed to simultaneously target immunologic and angiogenic pathways to inhibit tumor growth and progression. This combination is currently being evaluated in clinical trials, notably in combination with platinum-based chemotherapies for NSCLC[1].

Other names: rilvegostomig + ramucirumab

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)

Beyond the preview

Go deeper on rilvegostomig + ramucirumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rilvegostomig + ramucirumab.

Explore the full profile